Q-omics provides the consensus-scored GUSBP6 profile across patient tissues and cancer cell-line models. GUSBP6 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GUSBP6 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, GUSBP6 RNA expression shows 9,373 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, BRCA, and THYM as cancer lineages where GUSBP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GUSBP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GUSBP6 survival associations across molecular data types. GUSBP6 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GUSBP6 RNA expression–survival associations across cancer types. High GUSBP6 expression shows unfavorable associations in KIRC, LUSC, LUAD, CESC and PAAD, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify HNSC as the clearest survival context for GUSBP6 RNA expression.
This table summarizes GUSBP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for GUSBP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GUSBP6 shows lower tumor expression in BRCA and STAD and higher tumor expression in THCA, KIRP and KIRC. The BRCA box plot shows higher GUSBP6 RNA expression in normal versus tumor tissue (log2 FC = −0.062, t-test p < 0.001).
This table shows molecular features associated with GUSBP6 in patient tissues and cancer cell lines. In patient samples, GUSBP6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
